 I. To estimate the proportion of subjects with persistent or recurrent high grade endometrioid or serous ovarian carcinoma who demonstrate a downregulation of monocarboxylate transporter 4 MCT4 in the ovarian stroma in response to exposure to topotecan topotecan hydrochloride and N-acetylcysteine NAC acetylcysteine as compared to topotecan alone. 